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 Abstract: 
Background:  Pediatric stroke investigators identified as their top research priority a clinical 
trial of corticosteroids for focal cerebral arteriopathy (FCA).  However, FCA is both rare and an 
acute condition making it infeasible to enroll the large sample sizes needed for a standard, 
confirmatory clinical trial.  We present a pragmatic approach to clinical trial design that may 
inform the approach to other rare disorders. 
Methods:   We surveyed pediatric stroke experts to determine the level of evidence that would 
impact their clinical management of FCA.  Incorporating survey results, a randomized group 
sequential Bayesian adaptive design was proposed based on a quantitative radiologic outcome 
measure.  The design sequentially determines based on accumulating information from the first 
patient whether intervention is better than control with high probability.  
Results:  Among 21 (100%) respondents, the probability of corticosteroid efficacy that would 
lead them to treat was 30% (median).  The probability of efficacy that would make them 
unwilling to randomize (because they would feel all children should receive corticosteroids) was 
70%.    Simulation studies show that a total of 42 enrolled subjects controls the type I error rate 
at the desired level 0.2 and yields 80% power to detect the difference in mean change of 1.6.  
Conclusions:  Designs in rare diseases require special considerations; this is especially true for 
this childhood disease, which is both uncommon and acute. This design has incorporated expert 
consensus to establish the criteria for success, incorporates formal monitoring rules for safety, 
and futility or efficacy rules to stop early.        
Keywords: Bayesian adaptive trial design, rare disease, pediatric stroke, Sequential monitoring 
rule. 
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Introduction: 
In a Delphi consensus process, pediatric stroke investigators identified a clinical trial of 
corticosteroids for the treatment of focal cerebral arteriopathy of childhood (FCA) as the highest 
research priority for their field.1  FCA is a life-threatening inflammatory disease of cerebral 
arteries that progresses over days to weeks and causes arterial ischemic stroke in otherwise 
healthy children.2   In the absence of clinical trial data, clinicians have begun to employ 
corticosteroid therapy.3, 4  However, there are potential downsides:  experimental evidence 
suggests that the post-stroke inflammatory response has beneficial (in addition to detrimental) 
effects, with roles in infarct resolution, and brain remodeling and repair.5  Hence, pediatric 
stroke experts agree on the need for a clinical trial to guide FCA management.1 
 However, design of an FCA trial faces two major challenges:  the rarity of FCA and its 
acuity.  Although FCA is a common cause of childhood arterial ischemic stroke, ischemic stroke 
in children is rare, occurring in approximately 1.3 per 100,000 US children (non-neonates) per 
year.6   Although the incidence of FCA has not been established, it causes ≈10% of childhood 
arterial ischemic strokes,7 so has an annual incidence of ≈1.3 per 1,000,000 US children.  
Hence, in the US population of 74 million children, there are likely <100 annual FCA cases 
nationwide.  The acuity of FCA presents additional challenges; while most rare disease clinical 
trials study chronic diseases and take advantage of established patient cohorts, an FCA trial 
needs to rapidly identify and treat acute incident cases, before the arteriopathy progresses.   
 With a traditional trial design, the sample size is chosen such that the study has a certain 
amount of power for a minimum clinically important effect with the standard two-sided alpha 
level of 0.05.  This allows us to be “95% confident” that if we observe a treatment effect, then it 
is not due to chance alone. Likewise, if we do not observe a treatment effect, it is not due to lack 
of power. For a trial of a rare disease like FCA, this approach may result in an infeasible sample 
size, accomplishable only with hundreds of enrolling sites and a long enrollment window.  
Biomedical ethicists have argued that, for ethical reasons, the overall significance level should be 
adjusted in settings when clinicians would change clinical practice with a level of confidence 
lower than 95%.8  A lower alpha level reduces the necessary sample size for a trial, and hence 
reduces the number of participants randomized to the inferior therapy.  Others have suggested 
that approaches to sample size calculation ought to be different for rare diseases and need to 
take into account a variety of assumptions about the treatment effect, as well as input from the 
scientific community.9 In this paper, we describe how we designed a FCA corticosteroid trial—
the FOcal Cerebral Arteriopathy Steroid (FOCAS) trial—by seeking expert input to establish 
what would be considered a “good” probability that corticosteroids are better. The trial design 
operating characteristics are provided.   This approach may be useful to investigators designing 
clinical trials for other rare diseases.   
 
Material and methods:   
We approached the FOCAS trial design with the goal of obtaining the level of evidence sufficient 
to change current clinical practice while providing a feasible approach for a rare disease in an 
acute setting.  The proposed intervention is corticosteroid therapy (a standard 3-day course of 
IV methylprednisolone followed by oral prednisone) versus control group (standard care); both 
the treatment and control groups will receive standard therapy of oral aspirin and supportive 
care.  The primary endpoint is the change in the FCA Severity Score (FCASS; a quantitative 
radiologic measure of the arteriopathy severity) from baseline to 1 month post enrollment.2 
Safety outcome is a binary indicator taking 1 for a safe intervention and 0 for toxic intervention 
which would lead to any serious adverse event. The maximum sample size will be 50 children to 
be enrolled at 25 sites including the loss-to-follow-up which will not exceed 20% approximately. 
The primary analysis is intention-to-treat and will include all randomized children.  We adopt 
the idea from a Prospective Randomized Open, Blinded End-point (PROBE) design because 
corticosteroids cause behavioral side effects that preclude double-blinding; the 
neuroradiologists will measure the FCASS blinded to both treatment arm and time.10      
Expert Survey:  To determine the appropriate criteria for success for the trial, we 
designed a survey of pediatric stroke experts (full survey available, Online Supplemental 
Material).  The survey first established current practices concerning the use of IV corticosteroids 
for the treatment of FCA.  We also queried, using a Likert scale, current perceptions regarding 
the safety and benefit of corticosteroid therapy.  We then asked, “What probability of efficacy 
would lead you to treat FCA with corticosteroids?”  We repeated this question with two 
definitions of efficacy:  improved imaging biomarkers (arteriopathy progression and infarct 
volume) and improved 12-month neurological outcomes (using the Pediatric Stroke Outcome 
Measure, or PSOM).  The survey provided examples: “If you could tell a family that the 
treatment has a 50% chance of improving their child’s 12-month outcome, would that be enough 
for you to treat?”  To establish stopping rules for the trial, we also asked what probability of 
efficacy would make them unwilling to randomize their next patient due to efficacy or due to 
futility, and asked about acceptable levels of serious adverse effects.   
 We applied the survey in-person, taking advantage of an investigator meeting for an 
NIH-funded multicenter observational study of childhood arterial ischemic stroke (the Vascular 
effects of Infection in Pediatric Stroke, or VIPS, study).11  After distributing paper copies of the 
survey to 21 experts, the FOCAS PI (H.J.F.) verbally explained the intent of the survey and then 
guided the respondents through the individual questions.  We then collected and compiled the 
survey responses, and used descriptive statistics to summarize the results. 
Overview of FOCAS trial design:  We consider a multi-site, two-arm randomized clinical 
trial in which patients are enrolled in each site, and patients are randomized to either an 
intervention arm or control arm in a fixed ratio 1:1.  For each enrolled patient, FCASS 
measurements are collected at baseline and 1 month to assess potential benefit of the 
intervention based on the change of FCASS measurements, and are followed by 3 months to 
assess adequacy of 1 month of therapy by identifying relapses.  Also, infarct volume at 1 month, 
arteriopathy relapse, serious adverse events, and prevalence of acute herpesvirus infection will 
be measured as secondary outcomes.  The primary objective is to determine whether 
corticosteroid intervention improves the change of imaging outcomes (FCASS measurements) 
between baseline and 1 month of children with symptomatic FCA compared to the control.  Our 
design has interim analyses to monitor safety, futility and efficacy.  The interim analysis is 
performed at frequent looks, i.e., after every 10 subjects complete 1 month.  The trial may 
terminate early if the intervention is superior or futile compared to the control.  The proposed 
Bayesian monitoring rule based on the change from baseline to 1 month in FCASS 
measurements yields type I/II error by rejecting/accepting the null hypothesis, which states that 
there is no difference between intervention and control, assuming the null hypothesis is true.  
The errors are controlled by the test boundaries calibrated from simulations under the Bayesian 
framework.  In addition to the early stopping for efficacy and futility, we monitor the safety of 
intervention and allow early stopping of the trial due to toxic intervention.  Moreover, the 
FOCAS trial design identifies optimal duration for the intervention at the end of trial by 
assessing the probability to relapse for subjects showing an initial improvement, i.e., that the 
FCASS is worsening at 3 month compared to 1 month.  
Statistical models:  Index patients and sites by 𝑖 = 1, … , 𝑛𝑗 and 𝑗 = 1, … , 𝐽.  Let 𝐺𝑖𝑗  be an 
experimental condition indicator denoting E or C for intervention or control, respectively, which 
the 𝑖th subjects in the 𝑗th site are treated.  Let 𝑌𝑖𝑗 denote an outcome of the 𝑖th subject in the 𝑗th 
site for the observed change of FCASS measurement from baseline to 1 month (i.e., 1 month 
FCASS measurement -baseline FCASS measurement) and 𝑍𝑖𝑗 denote a binary safety outcome of 
the 𝑖th subject in the 𝑗th site with 𝑍𝑖𝑗 = 1 indicating that the 𝑖th subject in the 𝑗th site did not 
experience serious adverse events.  We model the efficacy outcome as 
𝑌𝑖𝑗 = 𝛼𝑗 + 𝜃𝐺𝑖𝑗 + 𝜀𝑖𝑗 , 
where 𝛼𝑗 describes the effect at site 𝑗, 𝜃𝐺𝑖𝑗 characterizes the effect of treatment which the 𝑖th 
patient in the 𝑗th site will be assigned (i.e., 𝐺𝑖𝑗 = 𝐸 or 𝐶), and the error term 𝜀𝑖𝑗 follows a normal 
distribution with mean 0 and variance 𝜎2.  The parameters 𝛼𝑗 , 𝑗 = 1, … , 𝐽, 𝜃𝐸, 𝜃𝐶 and 𝜎
2 are 
estimated under a Bayesian framework. We assume that 𝛼𝑗, 𝑗 = 1, … , 𝐽 are independently 
distributed from a normal variable with mean 𝑎 and variance 𝜉2 and the treatment effect  𝜃𝑔, 
𝑔 = 𝐸 or 𝐶 follows a normal distribution with the mean 𝜇𝑔 and variance 𝜂𝑔
2. We also assign 𝜎2 an 
inverse-gamma distribution with shape parameter 𝑤1 and rate parameter 𝑤1/𝑤2. For rare 
disease trials, since conventional vague prior distributions are often problematic for small 
samples, it is required to more care for the selection of hyperparameters - 𝑎, 𝜉, 𝜇𝑔 , 𝜂𝑔, 𝛾1 and 𝛾2.  
Appendix A provides the details of prior specification with reasonable hyperparameters for rare 
disease trial.  We next model the safety outcome for intervention as 
𝑍𝑖𝑗  ~ 𝐵𝑒𝑟 (𝜋𝐺𝑖𝑗), 
where 𝜋𝐺𝑖𝑗 denotes the safety probability for treatment 𝐺𝑖𝑗.  In this study, we are mostly 
concerned about the safety of the intervention group, but our proposed safety monitoring 
approach can be applied to both arms. This approach will be reviewed in addition to ongoing 
review by independent medical safety monitor.  We assign 𝜋𝐸 a non-informative beta prior with 
shape parameters 𝜙𝜈 and 𝜙(1 − 𝜈).  The selection of hyperparameters 𝜙 and 𝜈 are suggested in 
Appendix A.  Prior publications of FCA treatment with corticosteroids have not reported adverse 
effects. 3, 4  Furthermore, we do not expect that FCASS would be measured differently if there is 
a safety issue.  So, it is reasonable to assume that 𝑌𝑖𝑗 is independent of 𝑍𝑖𝑗.  If there was a prior 
belief that safety and efficacy are correlated, then we could add a term for safety effect on the 
FCASS measurements in  𝑌𝑖𝑗.  Lastly, under the Bayesian framework, we generate the sample 
from the posterior distribution, which is proportional to likelihood function multiplied by the 
prior distribution, using the Markov Chain Monte Carlo algorithm with Gibbs sampler.12  We 
provide the detail of posterior distribution based on our statistical model in Appendix B.  
Monitoring rules:  The FOCAS trial design monitors efficacy, futility and safety.  Suppose 
that the proposed design has 𝐾 − 1 interims and an interim analysis will be conducted after the 
enrollment of each cohort (e.g., every 10 subjects) to determine whether the trial should be 
terminated early for efficacy, futility and safety.   The final analysis will be performed after a 
follow-up period of 3 months for the last subject.  Let 𝐷𝑎𝑡𝑎𝑘 denote the accumulating data at the 
𝑘th analysis.  To define monitoring rule, let δ denote the maximum of acceptable rate of any 
serious adverse event for intervention.  The value of δ is pre-specified by the survey results for 
FOCAS trial design.  Then, 1-δ denotes the minimum of acceptable rate to say the intervention is 
safe enough.  Let 𝑐1, 𝑐2 and 𝜀 be pre-specified probability cutoffs obtained by preliminary 
simulation-based calibration.  We searched the cutoffs in a range identified from the survey 
results to save several rounds of calibrations to obtain the target type I/II error rates.  We 
provide a detailed explanation in Appendix C.  For the interim analysis at 𝑘 = 1, … , 𝐾 − 1, the 
decision rule are as follows: 
1. Stop the trial for superiority of intervention over control if 
𝑃{𝜃𝐸 < 𝜃𝐶|𝐷𝑎𝑡𝑎𝑘} > 𝑐1. 
2. Stop the trial for futility of intervention over control if 
𝑃{𝜃𝐸 < 𝜃𝐶|𝐷𝑎𝑡𝑎𝑘} < 𝑐2. 
3. Stop the trial for safety if  
𝑃{𝜋𝐸 ≥ 1 − 𝛿|𝐷𝑎𝑡𝑎𝑘} < 𝑐3. 
If the trial is not stopped early, then at the last analysis (i.e., 𝑘 = 𝐾), it is concluded that 
intervention is superior to control if 
𝑃{𝜃𝐸 < 𝜃𝐶|𝐷𝑎𝑡𝑎𝐾} > 𝑐1. 
Our monitoring rule follows an adaptive group sequential method in order to allow us to 
terminate the trial early for superiority, futility or safety based on the accumulating data.13-16 The 
similar approach monitoring futility and toxicity was considered in Bayesian adaptive oncology 
clinical trials to identify a set of admissible doses – acceptably safe and efficacious doses- for the 
dose finding problem.17-19 Also, the futility monitoring rule was considered a lot in phase II 
oncology trials based on the response probability.20, 21 However, the adaptive sequential rule 
incorporating efficacy, futility and safety was never used for pediatric Strokes, and we propose a 
tailored monitoring rule for pediatric Stokes.  
 Consideration of duration of intervention:  We define arteriopathy relapse in 
corticosteroid intervention arm as a worsening FCASS measurement from 1 month to 3 months 
after initial improvement (i.e., reduction in FCASS from baseline to 1 month).  Let 𝐹1 and 𝐹3 
denote the FCASS measurement at 1 month and 3 months, respectively.  Let 𝑑 = 𝐹1 − 𝐹3.  If any 
2 subjects with d<0 are observed, then the duration of corticosteroid intervention arm will be 
extended to 3 months. The primary outcome will not be changed. Because relapse is so rare, the 
intervention duration is likely to be extended if we observed a relapse in only 2 subjects. 
 
Results:   
Of 21 pediatric stroke investigators present at the VIPS investigator meeting, all (100%) 
participated in the survey.  All respondents were pediatric stroke clinical experts; 20 were child 
neurologists and one was a pediatric hematologist.   Seventeen (81%) were from U.S. 
institutions; three were Canadian and one was Swiss.   The majority (13/21, 62%) currently treat 
some cases of FCA with corticosteroids.  Among those 13 who sometimes treat, the most 
common criterion for treatment was progressive FCA severity (11/13 respondents), followed by 
recurrent ischemic events (9/13 respondents).  Regarding the statement, “I think corticosteroids 
most likely benefit children with FCA”:  4% strongly agreed, 44% agreed, and 52% were neutral 
(none disagreed or strongly disagreed).  Regarding the statement, “I think corticosteroids most 
likely harm children with FCA”:  9% strongly disagreed, 74% disagreed, and 17% were neutral 
(none agreed or strongly agreed).  All (100%) agreed they would be willing to enroll patients in a 
trial that randomized children to corticosteroids versus standard therapy. 
 If efficacy is measured by imaging biomarkers, the probability of efficacy that would lead 
an investigator to treat was a mean of 38% (median 30%; range 10% to 90%).  If efficacy is 
measured by 12-month PSOM (neurological outcome), the probability of efficacy that would lead 
an investigator to treat was a mean of 34% (median 25%; range 10% to 90%).  With either 
metric, only a single respondent indicated that they would require a probability of efficacy >80% 
in order to treat. The probability of efficacy (by either metric) that would make them unwilling 
to randomize because of efficacy (they would feel all children should receive the effective 
intervention) was a median 70%. The most common response was 80% (7 of 21 respondents), 
and only a single investigator (4.8% of 21 respondents) provided a response greater than 80%.  
Hence, we chose a threshold of 𝑐1=81% for the probability of that corticosteroids are better than 
control.  The probability of efficacy (by either metric) that would make them unwilling to 
randomize because of futility (they would feel no children should receive the futile intervention) 
was a mean of 17% (median 10%).    Hence, we chose a threshold probability of efficacy of 
𝑐2=15% for our futility rule. The maximum acceptable proportion of severe/life-threatening 
adverse effects (assuming corticosteroids are effective) was a mean of 4% (range 1 to 15%). 
Hence we chose 8% as δ  for our safety monitoring rule, and set 𝑐3=20%. 
 Simulation study:  We evaluated the operating characteristics of the FOCAS trial design 
using simulations. We assume enrollment occurred at 21 sites (i.e., 2 patients/site) that all 42 
subjects reached the final visit.  The maximum sample size 42 for a trial in simulation takes into 
account the dilution of the treatment effect due missing data from the planned sample size for 
FOCAS trial (N=50).  Patients arrived according to a Poisson process with the accrual rate of 0.5 
patients per year and were equally randomized to receive either intervention or control.  Three 
interim analyses were planned when the first 10, 20, and 30 enrolled patients completed 1 
month and the FCASS was measured.  A final analysis was performed after the last patient 
completed follow-up.  We generated the data according to the scenarios described in the first 
column of Table 1 with the expected change of FCASS measured between baseline and 1 month 
for control (Δ𝐶) and intervention (Δ𝐸).  Based on FCASS data from the VIPS cohort, excluding 
two patients treated with IV steroids, the mean change in FCASS from baseline to 1 month was 
3.8 (standard deviation=3) for the control group.2  The simulation setting follows the same 
control group mean throughout and considers a range of effects for the intervention group with 
an equal variance for both groups.  In other words, for the 𝑖th patient in site 𝑗 which was 
assigned to intervention, the change of FCASS between baseline and 1 month follows a normal 
distribution with mean  Δ𝐸 and standard deviation 3.  Serious adverse events (SAE) were 
generated from a Bernoulli distribution with a rate of 4%. 
We set the type I error rate 𝛼 = 0.2 and power 80% to detect the difference in mean 
change of 1.6. Using an empirical approach to calibrate the cutoffs for the Bayesian monitoring 
rule (see Appendix C),  𝑐1 = 0.81 and 𝑐2 = 0.15 were identified in order to achieve our desired 
type I and II error rates.  In addition, we identified 𝑐3=0.2 as an appropriate safety monitoring 
cutoff (figure 1).  Table 1 shows the results based on 10,000 simulations.  The FOCAS trial 
design preserved the overall type I error rate at the level of 0.195 (see the second scenario) and 
yielded power 81.3% when the difference in mean change of FCASS between corticosteroids and 
control was 1.6 (i.e., the fourth scenario).  The proposed design is compared with a conventional 
design using a one-sided two-sample t-test statistics with a level of significance 0.2 at the end of 
the trial.  The conventional design has no interim monitoring, and the total planned number of 
patients are required to be enrolled.  However, our proposed design identifies a treatment effect 
earlier and we save 30-55% of patients.  This is a remarkable benefit of the proposed design 
especially for a rare disease.  
Sensitivity analysis:  We evaluated the proposed design for the early stopping when the 
SAE rate varies with 20% and 25%, which are larger than the threshold 𝛿= 0.08, to consider a 
case where the rate is beyond the maximum of survey results accepting the safety issues.  We 
compared the results with the SAE rate 4%.  The left panel of Figure 1 shows that the trial stops 
earlier for high SAE rate with 73-86%, because it clearly detects serious events from 8%.  It 
saves more than 50% of patients from the toxic drug.  Also, when the drug is safe (i.e., the SAE 
rate is 4%), we almost never stopped early and our trial avoids erroneous decision for safety 
monitoring.   The right panel of Figure 1 shows the results of the FOCAS trial design when there 
is a site effect or when the site effect is more variable compared to the fourth scenario of Table 1.  
Note that the site effect was generated from a normal distribution with mean 0 and standard 
deviation 𝜏, and the FCASS change is now generated from 𝑌𝑖𝑗~𝑁(Δ𝐺𝑖𝑗 , 𝜏
2 + 32), where 𝐺𝑖𝑗  is 
either 𝐸 or 𝐶.  Since the sample size was calculated with 𝜏2=0, the rejection probability which 
indicates the power under the fourth scenario in Table 1 becomes smaller as the variability of the 
site effect increases. However, the mean sample size is mostly similar regardless of the 
variability of the site effect. Moreover, we investigated the operating characteristic of the 
proposed design when the errors are not normally distributed.  We generated the data under the 
same setting as Table 1, but with two different non-normal error distributions, including t 
distribution with degrees of freedom 2.25 and uniform distribution on interval (-5.2, 5.2).  Those 
parameters are selected to obtain the same variability as Table 1 but the distribution has fat-tail 
or flat-tail, respectively. The results are presented in Table 2. We notice that a moderate 
departure from normality does not cause a big difference in the operating characteristics. Both 
type I and II errors are preserved at the nominal level. 
Discussion: 
We present a pragmatic, adaptive clinical trial design, with criteria for trial success based on the 
level of evidence needed to impact clinical practice.   We have demonstrated the trial operating 
characteristics under a variety of assumptions.  
  In the VIPS observational study, the well-performing sites enrolled an average of one 
FCA case per site per year.7  If enrollment in FOCAS, as an interventional trial, is half of 
enrollment in VIPS, then patients would enroll 0.5 cases/site/year, or 2 cases/site over a 4-year 
enrollment period.  We need 25 sites to enroll 50 patients over four years.  The proposed design 
allows for a feasible study, accomplishable within the typical 5 year NIH funding period. 
We propose that several factors make this pragmatic approach reasonable for the FOCAS 
trial design: (1) FOCAS will study standard doses of old medications with well-established safety 
profiles commonly used for other pediatric disorders.  (We will not seek a new FDA label.)  (2) 
Alternative therapies for FCA do not exist, and untreated FCA often progresses. (3) Most 
pediatric stroke experts already employ corticosteroids for select cases of FCA, and perceive it to 
be safe.   Hence, to be convinced to treat FCA with corticosteroids, clinicians require a lower 
than usual level of confidence that the treatment is effective.    
We also propose that this approach is more ethical, minimizing the number of children 
who would ultimately receive the inferior therapy.   We anticipate that this assurance—that we 
will minimize unnecessary randomization—will improve participation in the clinical trial.  It 
would be less likely to enroll children into a trial designed to prove efficacy at a higher level than 
what they feel necessary for clinical practice.   
Conclusions:  Other rare diseases may be similar to FCA in that clinicians would be 
comfortable with a lower level of confidence regarding treatment efficacy because of either the 
severity of disease or the safety of the intervention.  This approach to trial design— applying the 
probability of efficacy needed to change clinical practice based on expert consensus and 
incorporating frequent opportunities to stop early—may help make the study of interventions 
for rare disease more feasible. 
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Figure:  
Figure 1. Plot of sensitivity analysis for serious adverse event (SAE) rate (left panel) and 
variability of site effect (right panel) when the difference of FCASS measured between 
corticosteroids and control was -1.6 (i.e., the fourth scenario). 
 
 
 
 
 
  
Tables: 
Table 1. Results for FOCAS trial design under five scenarios. 
Scenario 
(Δ𝐶 ,Δ𝐸) 
Rejection probability Mean sample size Early stopping 
probability 
FOCAS Conventional FOCAS Conventional  superiority futility 
(3.8, 4.0) 0.141 0.147 35.62 42 0.123 0.136 
(3.8, 3.8) 0.195 0.2 35.15 42 0.168 0.108 
(3.8, 2.8) 0.589 0.582 28.68 42 0.504 0.027 
(3.8, 2.2) 0.813 0.799 23.03 42 0.721 0.009 
(3.8, 1.8) 0.912 0.896 19.40 42 0.842 0.004 
 
Table 2. Sensitivity analysis results for FOCAS trial design under non-normal error 
distribution. 
Error 
distribution 
Scenario 
(Δ𝐶 , Δ𝐸) 
Rejection 
probability 
Mean sample 
size 
Early stopping probability for 
superiority futility 
Fat-tailed (t 
distribution)  
(3.8, 4.0) 0.051 39.89 0.043 0.048 
(3.8, 3.8) 0.084 39.69 0.067 0.032 
(3.8, 2.8) 0.650 29.13 0.538 0.004 
(3.8, 2.2) 0.920 19.02 0.858 0.002 
(3.8, 1.8) 0.975 14.75 0.946 0.001 
Flat-tailed 
(uniform) 
(3.8, 4.0) 0.144 35.39 0.126 0.142 
(3.8, 3.8) 0.194 35.03 0.168 0.114 
(3.8, 2.8) 0.590 28.71 0.505 0.028 
(3.8, 2.2) 0.809 23.21 0.721 0.011 
(3.8, 1.8) 0.909 19.70 0.836 0.005 
 
Online Supplemental Material:  Appendix 
A. Prior specification. 
A simple linear model is used to model the efficacy outcome 𝑌𝑖𝑗 with the site effect 𝛼𝑗 , 𝑗 = 1, … , 𝐽. 
For computational simplicity, we take 𝜉 = 𝜎𝜏 and 𝜂𝑔 = 𝜎𝑔𝑠𝑔 for 𝑔 = 𝐸 or 𝐶. This choice brings a 
normal-inverse-gamma conjugate prior described by 
𝛼𝑗|𝜎
2 ~ 𝑁(𝑎, 𝜎2𝜏2) 
𝜃𝐺𝑖𝑗=𝑔|𝜎
2 ~ 𝑁(𝜇𝑔, 𝜎
2𝑠𝑔
2),   𝑔 = 𝐸 or 𝐶 
𝜎2 ~ 𝐼𝐺(𝑤1, 𝑤1/𝑤2), 
where 𝑎, 𝜏2, 𝜇𝑔, 𝑠𝑔
2, 𝑤1, and 𝑤2 are hyperparameters. Since all FCASS measurements obtained 
from multiple sites will be scored centrally, it is reasonable to assume small variability for the 
site effect.  So, we assign the site effect parameter 𝛼𝑗 a normal prior distribution with 𝑎 = 0 and 
𝜏2 = 0.1. Conditional prior distributions of treatment effect 𝜃𝐸 or 𝜃𝐶 given 𝜎
2 are specified by 
historical data and the regularized vague prior approach using the fact that any change in an 
input variable within two standard deviation below the mean and two standard deviation above 
the mean most likely results in the difference of response variable.  This approach would provide 
more reliable inference for a rare disease by assigning prior distributions which are vague 
enough to cover the plausible values of the parameter. Based on the VIPS data, we obtained 
 𝜇𝐶 = 3.8 for prior mean and 𝜎 = 3.  Also, the FCASS change from baseline to 1 month ranges 
between 0 and 9. Thus, 𝑠𝐸 = 𝑠𝐶 = 1 are specified under the equal variance assumption.  The 
prior distribution of 𝜎2 is the inverse gamma distribution with shape parameter 𝑤1 and rate 
parameter 𝑤1/𝑤2.  The prior mean of 1/𝜎
2 is 𝑤2 and the prior effective sample size is 𝑤1, which 
is an intuitive measure for the amount of information provided by the prior (Morita et al., 
2008).  The prior effective sample size is generally small to ensure that the prior does not 
provide an inappropriate amount of information.  Here, we take 𝑤1 = 1/2.  The value of 𝑤2 is 
chosen by the historical data, i.e., 𝑤2 = 1/3
2. Similarly, for the safety outcome, the prior mean of 
𝜋𝐸 is 𝜈 and the prior effective sample size is 𝜙.  We use default value of 𝜙 = 1.  From the 
physicians’ expert knowledge, 𝜈 is chosen by the expected probability of serious adverse event 
for intervention 0.04.  Thus, we have 𝜋𝐸  ~ 𝐵𝑒𝑡𝑎(0.04, 0.96). 
 
B. Posterior distribution. 
The FOCAS trial design uses a conjugate prior for the likelihood function for the observed data 
under the Bayesian framework.  This provides the closed form of posterior distribution for 
parameters and makes our design simple and convenient for inference.  Under the situation 
where the site effect and treatment effect are independent, we combine 𝛼1, … , 𝛼𝐽, 𝜃𝐸𝐼(𝐺𝑖𝑗 = 𝐸) 
and 𝜃𝐶𝐼(𝐺𝑖𝑗 = 𝐶) into a vector and consider the corresponding design matrix 𝑿𝑡 and covariance 
matrix 𝑽𝑡.  Let 𝑐 = 𝑤1 + 𝑛/2, 𝑒 = 𝑤1/𝑤2 + (𝝁𝑡
𝑇𝑽𝑡
−1𝝁𝑡 + 𝒚
𝑇𝒚 − 𝝁0
𝑇𝑽0
−1𝝁0)/2, where  
𝝁0 = (𝑽𝑡
−1 + 𝑿𝑡
𝑇𝑿𝑡)
−1(𝑽𝑡
−1𝝁𝑡 + 𝑿𝑡
𝑇𝒚) 
𝑽0 = (𝑽𝑡
−1 + 𝑿𝑡
𝑇𝑿𝑡)
−1 
Then, 
{𝛼1, … , 𝛼𝐽, 𝜃𝐸𝐼(𝐺𝑖𝑗 = 𝐸), 𝜃𝐶𝐼(𝐺𝑖𝑗 = 𝐶)}
𝑇
|𝒚 ~ 𝑀𝑉𝑡𝜈(𝝁0, (𝑒/𝑐)𝑽0) 
𝜎2|𝒚 ~ 𝐼𝐺(𝑐, 𝑒) 
𝜋𝐺𝑖𝑗|𝒛 ~ 𝐵𝑒𝑡𝑎(𝜙𝜈 + ∑ 𝑧𝑖𝑗
𝑖
, 𝜙(1 − 𝜈) + ∑(1 − 𝑧𝑖𝑗)
𝑖
), 
Where 𝑀𝑉𝑡𝜈(𝑨, 𝑩) denotes a multivariate t distribution with degrees of freedom 𝜈, location 
vector 𝑨 and shape matrix 𝑩, 𝜈 = 2𝑐 and 𝑧𝑖𝑗  denotes the number of observed serious adverse 
event.   
C. Calibration of cutoffs for Bayesian sequential monitoring rule 
The proposed Bayesian sequential monitoring rule involves three design parameters 𝑐1, 𝑐2 and 
𝑐3, where 𝑐1 controls type I error rate, which occurs from superiority stopping when the null is 
true, and 𝑐2 controls type II error rate, which occurs from futility stopping under the alternative.  
The value of 𝑐3 relates to the overall stopping rate due to safety, which does not matter with type 
I or II error for hypothesis testing.  Our proposed design is an adaptive design and it is not 
possible to analytically calculate the type I and II error rates.  Rather than analytic errors, we 
commonly determine the empirical type I and II error rates from simulation.  In this setting, we 
assign the initial values of 𝑐1 and 𝑐2, and perform simulation to calculate the empirical type I 
and II error rates.  Based on our experiences, the reasonable initial values of 𝑐1 and 𝑐2 are 1 − 𝛼 
and power, respectively.  The survey results also suggests to search the values of 𝑐1 and 𝑐2 over 
the range >=80% and <17%, respectively.  The suggestion will save several rounds of 
calibrations to obtain the target type I and II error rates as well as make sense with experts’ 
experience and knowledge.  If the type I error rate is lower/higher than the desirable level, we 
decrease/increase the value of 𝑐1, and if the calculated type II error rate is lower/higher than the 
desirable level, we decrease/increase the value of 𝑐2.  We repeat this calibration process until the 
desirable type I and II error rate are obtained.  Similarly, we vary the values of 𝑐3 until the 
desirable early stopping probability for safety is obtained. 
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